T 250 - Trimeris

Drug Profile

T 250 - Trimeris

Latest Information Update: 29 Mar 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trimeris
  • Class Antiplatelets; Antivirals; Vascular disorder therapies
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Parainfluenza virus infections

Most Recent Events

  • 29 Mar 2001 Discontinued-Preclinical for Parainfluenza virus infections in USA (Unknown route)
  • 02 Sep 1998 No-Development-Reported for Parainfluenza virus infections in USA (Unknown route)
  • 12 Jun 1995 Preclinical development for Parainfluenza virus infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top